Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PBMC immunomodulated with interferon tau
- Development stage
- Unknown
- Lead developer
- Nadezhda Women's Health Hospital
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Cell Therapies
- Administration
- Vaginal
01
Overview
PBMC immunomodulated with interferon tau (IFNt) is an experimental autologous cell therapy developed by Nadezhda Women's Health Hospital for the treatment of unexplained infertility and recurrent implantation failure (RIF). The therapy involves isolating a patient's peripheral blood mononuclear cells (PBMCs) and culturing them ex vivo with interferon tau, a type I interferon originally identified in ruminants. IFN-τ acts as an agonist at the interferon-alpha/beta receptor (IFNAR) on immune and endometrial cells, inducing the expression of interferon-stimulated genes (ISGs) and promoting an anti-inflammatory M2 macrophage phenotype. This modulation is intended to enhance endometrial receptivity and maternal immune tolerance toward the embryo. The treated cells are administered intrauterinely prior to embryo transfer in IVF or frozen embryo transfer (FET) cycles.
- Other names
- autologous peripheral blood mononuclear cells + interferon tauIFNt-modulated PBMCIFNt-PBMC
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on PBMC immunomodulated with interferon tau.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PBMC immunomodulated with interferon tau.